Search

Natera Inc

Lezárt

SzektorEgészségügy

417.04 1.73

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

405.56

Maximum

410.4

Fő mutatók

By Trading Economics

Bevétel

18M

-67M

Értékesítés

56M

753M

Egy részvényre jutó nyereség

-0.47

Profit margin

-8.897

Munkavállalók

6,135

EBITDA

20M

-45M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

-9.81% downside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 5.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

21B

59B

Előző nyitás

415.31

Előző zárás

417.04

Hangulat hírek alapján

By Acuity

50%

50%

67 / 340 Rangsor szerint Healthcare

Natera Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. okt. 2. 20:07 UTC

Natera Inc shares are higher amid a broadly advancing market, reflecting positive momentum as labor statistics influence expectations for future interest rates.

2026. okt. 1. 20:07 UTC

Natera Inc shares are declining, reversing earlier gains despite remaining above the 20-day moving average and near the upper end of the one-month range.

2026. szept. 30. 23:00 UTC

Natera Inc declined in after-market trading, settling below Wednesday's close after retreating from an early high, despite remaining higher over the past month.

2026. szept. 29. 19:15 UTC

Social Media

Natera Inc shares are modestly higher as social media buzz highlights positive cash flows and a potential cancer screening test amid market volatility.

2026. szept. 28. 20:07 UTC

Social Media
News

Natera's shares fell amid a broader market decline, despite RBC Capital raising its price target to $460 and maintaining an Outperform rating.

2026. szept. 25. 19:46 UTC

News
Social Media

RBC Capital raised its price target on Natera Inc to $460, maintaining an Outperform rating, as shares trade modestly higher amid strong market position.

2026. szept. 24. 23:01 UTC

Natera Inc is trading modestly lower in after-market hours, having retraced from an early gain and reflecting a cumulative decline since Thursday's close.

2026. szept. 22. 20:02 UTC

Social Media
News

Natera Inc's Signatera test received regulatory approval in Japan as a companion diagnostic for muscle-invasive bladder cancer, driving the stock sharply higher.

2026. szept. 21. 22:11 UTC

Natera Inc is trading modestly higher in after-market hours, remaining well above its 20-day moving average following a peak earlier in the session.

2026. szept. 18. 22:31 UTC

Natera Inc declined in after-market trading, moving lower since Friday's close, despite previously trading above its 20-day moving average.

2026. szept. 17. 23:06 UTC

Natera Inc's shares traded flat in after-market hours, remaining 10.18% above the 20-day moving average amid positive economic indicators.

2026. szept. 16. 19:07 UTC

Natera Inc shares fell modestly lower, reaching a notable low today, though remaining above their 20-day moving average.

2026. szept. 15. 23:01 UTC

Natera Inc shares are higher in after-market hours following Tuesday's close, continuing a trend of four consecutive sessions that also closed higher.

2026. szept. 14. 19:26 UTC

News
Social Media

Natera Inc is gaining momentum as it breaks above September's value area. UBS raised its price target while maintaining a "buy" rating.

2026. szept. 11. 22:51 UTC

Natera Inc shares are lower in after-market hours, with no specific news identified to explain the movement. Broader market sentiment may be influencing trading.

2026. szept. 9. 20:07 UTC

News

UBS has raised its price target on Natera Inc. to $435, maintaining a Buy rating and contributing to a rise in shares during Wednesday's session.

2026. szept. 8. 23:06 UTC

Natera Inc. shares are higher in after-market trading, maintaining upward momentum since Tuesday's close despite an earlier pullback. The stock is above its 20-day moving average.

2026. szept. 3. 19:36 UTC

News

Baird raised Natera's price target to $376 from $348, maintaining an Outperform rating. Shares are higher since Wednesday's close amid easing interest rate concerns.

2026. szept. 2. 23:26 UTC

Natera Inc. shares are higher in after-market trading, continuing a strong performance over the past month, well above the 20-day moving average.

2026. szept. 1. 19:36 UTC

News
Event

Natera's Signatera test shows 100% predictive value for lymphoma treatment responses, boosting shares higher during Tuesday's session.

2026. aug. 31. 23:01 UTC

Natera Inc shares are higher in after-market trading, stabilizing near earlier highs amid broader economic concerns over potential interest rate hikes.

2026. aug. 28. 20:02 UTC

News

Natera Inc partners with Susan G. Komen to enhance breast cancer education. Shares are lower amid high trading volume and broader market pressures.

2026. aug. 27. 20:07 UTC

News

Natera partners with Angiex to use Signatera in a Phase I trial for AGX101, aimed at enhancing cancer treatment response evaluation. Shares are roughly flat.

2026. aug. 26. 19:26 UTC

Natera Inc's shares are higher today, reflecting a general market uptrend. The stock remains above its 20-day moving average and near a one-month high.

2026. aug. 24. 19:46 UTC

Natera Inc shares are lower today, pulling back from earlier session highs. Rising oil prices and geopolitical tensions impact overall market sentiment.

2026. aug. 21. 20:06 UTC

Natera Inc shares are higher today, rebounding from an early dip amid positive momentum in the biotechnology sector and overall market performance.

2026. aug. 20. 23:16 UTC

Natera Inc. shares are slightly higher in after-market hours, remaining near the upper end of their one-month range amid broader market pressure from rising yields.

2026. aug. 19. 20:02 UTC

Natera Inc shares are higher today amid a broader market rally, with notably increased trading volume indicating heightened investor interest.

2026. aug. 18. 23:36 UTC

Natera Inc shares are lower in after-market hours, with no specific news identified. Broader market sentiment is impacted by declines in the Nikkei 225 Index.

2026. aug. 17. 19:36 UTC

Social Media
News

Natera Inc reports second-quarter revenue of $752.8 million, exceeding expectations. Shares are higher as the company cites strong test volume growth and regulatory approvals.

Társak összehasonlítása

Árváltozás

Natera Inc Előrejelzés

Célár

By TipRanks

-9.81% elmozdulás lefelé

12 hónapos előrejelzés

Átlag 370.079 USD  -9.81%

Magas 475 USD

Alacsony 320 USD

21 Wall Street elemző 12 hónapos célárain alapulva a(z)Natera Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

21 ratings

20

Vétel

1

Tartás

0

Eladás

Hangulat

By Acuity

67 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Neutral

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.